Akari Therapeutics
Logotype for Akari Therapeutics PLC

Akari Therapeutics (AKTX) investor relations material

Akari Therapeutics Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Akari Therapeutics PLC
Q3 2026 earnings summary12 Nov, 2026

Executive summary

  • Preclinical oncology developer focused on PH1 RNA-splicing-modulating ADCs; AKTX-101 is the lead program, with IND-enabling work aimed at Phase 1 readiness. No product revenue generated.

  • Initiated GLP toxicology studies for TROP2-targeted AKTX-101; a mid-2027 Phase 1 start is planned, subject to additional financing.

  • Q3 2026 net loss was $4.8 million versus $6.4 million a year earlier; nine-month net loss was $24.1 million versus $12.0 million, including $12.1 million of non-cash impairment charges.

  • Preclinical studies showed AKTX-101 activity in urothelial models with limited response or acquired resistance to approved ADCs.

Financial highlights

  • Q3 operating expenses were $4.7 million versus $7.4 million YoY; nine-month operating expenses were $25.0 million versus $14.0 million, primarily reflecting impairment charges.

  • Q3 R&D expense was $2.1 million versus $0.2 million; nine-month R&D was $5.6 million versus $1.7 million, mainly driven by ADC preclinical development.

  • Q3 G&A expense was $2.6 million versus $2.0 million; nine-month G&A was $7.3 million versus $7.1 million, including one-time prior placement-agent termination costs.

  • Operating cash use was $9.8 million for 9M 2026 versus $7.5 million; financing provided $10.4 million, and cash plus restricted cash ended the period at $5.8 million.

Outlook and guidance

  • IND-enabling nonclinical and CMC/manufacturing work, including GLP toxicology and GMP supply, continues toward a planned mid-2027 Phase 1 trial for AKTX-101.

  • Priorities include further resistance-model data, expanding partnerships, and progressing CEACAM5-targeted AKTX-102.

  • Existing cash was expected to fund operations into Q1 2027; additional capital is required, and financing availability, terms, and timing remain uncertain.

  • Future R&D spending depends on funding; potential sources include equity or debt, collaborations, preclinical or clinical funding arrangements, licensing, or asset transactions.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Akari Therapeutics earnings date

Logotype for Akari Therapeutics PLC
Q4 202631 Mar, 2027
Akari Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Akari Therapeutics earnings date

Logotype for Akari Therapeutics PLC
Q4 202631 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Akari Therapeutics PLC is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune and inflammatory diseases. The company’s research primarily targets conditions involving the complement and leukotriene pathways, which play key roles in immune system regulation. Akari Therapeutics is headquartered in London, United Kingdom, and its shares are listed on the NASDAQ.